Articles tagged "IMPDH Inhibitor"

2022 American Transplant Congress
De Novo Donor-Specific Antibody Development with Mycophenolate versus Azathioprine in Lung Transplant Recipients
A. Prom¹, K. Walter², K. Gomez³, C. Doligalski¹, L. Lobo¹, R. Evans¹
¹UNC Health, Chapel Hill, NC, ²University of Michigan, Ann Arbor, MI, ³University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC
*Purpose: The effect of mycophenolate mofetil (MMF) or azathioprine (AZA) immunosuppression (ISN) regimens on de novo donor specific antibody (DSA) formation in lung transplant recipients…
2018 American Transplant Congress
Effects of the Addition of Mycophenolate Mofetil on Renal Outcomes in Liver Transplant Recipients: A Single Center Review
M. Henry, M. Vacha.
Nebraska Medicine, Omaha, NE.
Purpose: To evaluate the use of mycophenolate mofetil (MMF) and its effects on renal outcomes in liver transplant recipientsMethods: Adult liver transplant recipients from September…
2016 American Transplant Congress
A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial.
H. Ishida,¹ K. Tanabe,¹ S. Takahara,² N. Amada,³ K. Takahashi,⁴ H. Toma.⁵
¹Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan; ²Advanced Technology for Transplantation, Osaka University, Osaka, Japan; ³Surgery, JCHO Sendai Hospital, Sendai, Japan; ⁴Niigata Organ Transplant Foundation, Niigata, Japan; ⁵Urology, Toda Chuo Hospital, Toda, Saitama, Japan.
PURPOSE: To compare the clinical outcomes of mizoribine (MZR; 12 mg/kg/day) and mycophenolate mofetil (MMF; 2000 mg/day) in combination with tacrolimus (FK), basiliximab (SIM), and…
2015 American Transplant Congress
Intra-Lymphocyte Concentrations of Mycophenolic Acid Correlate With the Incidence of Early Graft Rejection in Renal Transplant Recipients
Z. Md Dom,² J. Coller,² R. Carroll,³ A. Somogyi,² B. Sallustio.¹
¹Clinical Pharmacology, The Queen Elizabeth Hospital, Adelaide, Australia; ²Discipline of Pharmacology, Univeristy of Adelaide, Adelaide, Australia; ³Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia.
Introduction: Although routine therapeutic drug monitoring of mycophenolic acid (MPA) concentrations in plasma has been recommended to individualize MPA doses in transplant recipients, little is…